Kezar Life Sciences KZR 深 沪
等待开盘 09-18 09:30:00 美东时间
3.74
-0.010
-0.27%
华盛通- 最 高3.85
- 今 开3.75
- 成交量 1.70万股
- 最 低 3.71
- 昨 收 3.75
- 总市值 2738.84万
- 52周最高 9.18
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.6201
- 委 比 24.38%
- 总股本 732.31万
- 历史最高 363.27
- 量 比 1.53
- 振 幅 3.73%
- 历史最低 3.6201
- 每 手 1
- 风险率 1.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kalamazoo Resources Schedules General Meeting for Shareholder Resolutions
The latest announcement is out from Kalamazoo Resources Ltd. ( ($AU:KZR) ). Kal...
08-26 15:28
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials
Kezar Life Sciences ( ($KZR) ) has released its Q2 earnings. Here is a breakdow...
08-14 12:31
Kalamazoo Resources Ltd. Announces Trading Halt Pending Acquisition News
An announcement from Kalamazoo Resources Ltd. ( ($AU:KZR) ) is now available. K...
07-25 08:29
Kezar Life Sciences Announces FDA Lifted Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib For Autoimmune Hepatitis
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of
07-16 04:41
Kalamazoo Resources Updates Registered Office Address
Kalamazoo Resources Ltd. ( ($AU:KZR) ) has issued an announcement. Kalamazoo Re...
06-27 16:57
Kezar Life Sciences Q1 EPS $(2.27) Beats $(2.61) Estimate
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(2.61) by 13.03 percent. This is a 24.33 percent increase over losses of $(3.00) per share
05-14 13:37
快讯 | Kezar Life Sciences公布2025年第一季度财务报告并提供业务更新
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides B...
05-14 04:01
Kezar Life Sciences Appoints New Principal Accounting Officer
Kezar Life Sciences ( ($KZR) ) has shared an update. On March 27, 2025, Kezar L...
04-02 04:29
Kezar drops after Q4 results and mid-stage data for lead asset
Kezar Life Sciences (NASDAQ:KZR) traded lower on Tuesday after the company announced its Q4 2024 financial results alongside data from a mid-stage trial for its lead asset zetomipzomib in patients wit...
03-26 02:57
Positive Report for Kezar Life Sciences (KZR) from William Blair
Kezar Life Sciences (KZR – Research Report) received a Buy rating and price tar...
02-28 20:19
